Karyopharm Therapeutics (KPTI) Non Operating Income (2013 - 2025)

Karyopharm Therapeutics has reported Non Operating Income for 13 years, with the latest figure at $21.7 million in Q4 2025.

• For the quarter ending Q4 2025, Non Operating Income rose 5437.76% year-over-year to $21.7 million; the trailing twelve-month figure through Dec 2025 stood at $10.8 million (down 76.85% YoY), and the FY2025 full-year result was $840000.0, down 98.05% from the prior year.
• Non Operating Income for Q4 2025 stood at $21.7 million, up from -$17.9 million in the prior quarter.
• The five-year high for Non Operating Income was $52.0 million in Q2 2024, with the low at -$25.9 million in Q4 2021.
• Historically, Non Operating Income has averaged $598900.0 across 5 years, with a median of -$142000.0 in 2022.
• Annual changes were most pronounced in 2022 — Non Operating Income plunged 30322.22% — and 2024, when it surged 173163.33%.
• Karyopharm Therapeutics' Non Operating Income stood at -$25.9 million in 2021, then jumped by 82.41% to -$4.6 million in 2022, then jumped by 95.38% to -$211000.0 in 2023, then surged by 285.78% to $392000.0 in 2024, then jumped by 5437.76% to $21.7 million in 2025.
• The last three Non Operating Income figures came in at $21.7 million (Q4 2025), -$17.9 million (Q3 2025), and -$12.8 million (Q2 2025), per Business Quant data.